Seminars in Oncology
Volume 30, Issue 3 , Pages 382-389 , June 2003

Recommendations of follow-up after treatment of germ cell tumors

  • G.Varuni Kondagunta

      Affiliations

    • Department of Genitourinary Oncology, Memorial Sloan-Kettering Cancer Center, and the Department of Medicine, Weill Medical College of Cornell Univeristy, New York, NY, USA
    • ,
  • Joel Sheinfeld

      Affiliations

    • Department of Genitourinary Oncology, Memorial Sloan-Kettering Cancer Center, and the Department of Medicine, Weill Medical College of Cornell Univeristy, New York, NY, USA
    • ,
  • Robert J. Motzer

      Affiliations

    • *Address reprint requests to Robert J. Motzer, MD, Department of Genitourinary Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021 USA
    • Department of Genitourinary Oncology, Memorial Sloan-Kettering Cancer Center, and the Department of Medicine, Weill Medical College of Cornell Univeristy, New York, NY, USA

References 

  1. Greenlee RT, Hill-Harmon MB, Murray T, et al.  Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36
  2. DeVita VJ, Hellman S, Rosenberg SA. Cancer: Principles & Practice of Oncology. Philadelphia, PA: Lippincott-Raven,; 2001;
  3. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242–253
  4. Motzer RJ, Sheinfeld J, Mazumdar M, et al.  Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol. 1995;13:2700–2704
  5. Fossa SD, Horwich A, Russell JM, et al.  Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17:1146
  6. Warde P, Gospodarowicz M, Panzarella T, et al.  Management of stage II seminoma. J Clin Oncol. 1998;16:290–294
  7. Klepp O, Olsson AM, Henrikson H, et al.  Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol. 1990;8:509–518
  8. Wishnow KI, Johnson DE, Swanson DA, et al.  Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology. 1989;34:339–343
  9. Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al.  Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse. J Clin Oncol. 2001;19:2020–2025
  10. Davis BE, Herr HW, Fair WR, et al.  The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol. 1994;152:111–114
  11. Toner GC, Motzer RJ. Poor prognosis germ cell tumors: Current status and future directions. Semin Oncol. 1998;25:194–202
  12. NCCN practice guidelines for testicular cancer. National Comprehensive Cancer Network. Oncology (Huntington). 1998;12:417–462
  13. Livsey JE, Taylor B, Mobarek N, et al.  Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for followup. J Clin Oncol (R Coll Radiol). 2001;13:296–300
  14. Francis R, Bower M, Brunstrom G, et al.  Surveillance for stage I testicular germ cell tumours: Results and cost benefit analysis of management options. Eur J Cancer. 2000;36:1925–1932
  15. Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation versus observation: A cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol. 1996;14:2933–2939
  16. Harvey ML, Geldart TR, Duell R, et al.  Routine computerized tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer—A necessary risk?. Ann Oncol. 2002;13:237–242
  17. Sharir S, Jewett MA, Sturgeon JF, et al.  Progression detection of stage I nonseminomatous testis cancer on surveillance: Implications for the followup protocol. J Urol. 1999;161:472–476
  18. Gietema JA, Meinardi MT, Sleijfer DT, et al.  Routine chest x-rays have no additional value in the detection of relapse during routine followup of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol. 2002;13:1616–1620
  19. White PM, Adamson DJ, Howard GC, et al.  Imaging of the thorax in the management of germ cell testicular tumors. Clin Radiol. 1999;54:207–211
  20. Travis LB, Curtis RE, Storm H, et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89:1429–1439
  21. Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Intern Med. 2002;136:463–470
  22. Wanderas EH, Fossa SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer. 1997;33:244–252

PII: S0093-7754(03)00098-8

Seminars in Oncology
Volume 30, Issue 3 , Pages 382-389 , June 2003

Article Tools